S. Schnittman

发表

The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4.

C H Fox, C. Fox, M. Baseler, 1989, Science.

Lymphoid organs function as major reservoirs for human immunodeficiency virus.

A. Fauci, G. Pantaleo, D. Kotler, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Human Immunodeficiency Virus Proviral DNA from Peripheral Blood and Lymph Nodes Demonstrates Concordant Resistance Mutations to Zidovudine (Codon 215) and Didanosine (Codon 74)

M. Wainberg, O. Weislow, D. Mayers, 1998 .

Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections.

M. Niu, D. Stein, S. Schnittman, 1993, The Journal of infectious diseases.

Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual.

J. Timpone, D. Stein, S. Schnittman, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

O. Weiland, P. Thuluvath, G. Everson, 2014, Gut.

Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy

C. Fox, A. Fauci, G. Pantaleo, 1998, Nature Medicine.

NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection.

A. Fauci, G. Pantaleo, S. Koenig, 1991, Annals of internal medicine.

CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals.

J. Justement, A. Fauci, J. Greenhouse, 1992, Journal of immunology.

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations

Mary E. Wilson, J. Hughes, J. Phair, 1995 .

Host defense againstMycobacterium-avium complex

A. Fauci, H. Lane, L. L. Gosey, 1988, Journal of Clinical Immunology.

Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: The cytomegalovirus retreatment trial

J. Phair, A. Wu, A. Friedman, 1996 .

Infection of CD8+ T lymphocytes with HIV. Requirement for interaction with infected CD4+ cells and induction of infectious virus from chronically infected CD8+ cells.

M. Baseler, A. Fauci, G. Pantaleo, 1991, Journal of immunology.

CD8+ cytolytic T lymphocytes become infected in vitro in the process of killing HIV‐1‐infected target cells

L. Moretta, A. De Maria, S. Colombini, 1994, European journal of immunology.

Human immunodeficiency virus (HIV) infection in CD4+ T lymphocytes genetically deficient in LFA-1: LFA-1 is required for HIV-mediated cell fusion but not for viral transmission

A. Fauci, G. Pantaleo, L. Butini, 1991, The Journal of experimental medicine.

Thymic microenvironment induces HIV expression. Physiologic secretion of IL-6 by thymic epithelial cells up-regulates virus expression in chronically infected cells.

B. Haynes, A. Fauci, L. Whichard, 1991, Journal of immunology.

Frequent detection of HIV-1-specific mRNAs in infected individuals suggests ongoing active viral expression in all stages of disease.

A. Fauci, H. Lane, P. Pierce, 1991, AIDS research and human retroviruses.

Evidence for susceptibility of intrathymic T-cell precursors and their progeny carrying T-cell antigen receptor phenotypes TCR alpha beta + and TCR gamma delta + to human immunodeficiency virus infection: a mechanism for CD4+ (T4) lymphocyte depletion.

B. Haynes, J. Justement, M. Baseler, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Antiviral Activity of Nucleoside Analogues During Short-Course Monotherapy or Dual Therapy: Its Role in Preventing HIV Infection in Infants

G. Gray, J. McIntyre, A. Violari, 2006, Journal of acquired immune deficiency syndromes.

Summary of the National Institutes of Health workshop on primary human immunodeficiency virus type 1 infection.

S. Schnittman, M. Niu, J. Jermano, 1993, AIDS research and human retroviruses.

Emergence of unusual opportunistic pathogens in AIDS: a review.

J. Timpone, S. Schnittman, J. Gradon, 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evidence for susceptibility of intrathymic T cell precursors to human immunodeficiency virus infection: a mechanism for T4 (CD4) lymphocyte depletion.

B. Haynes, J. Justement, M. Baseler, 1990, Transactions of the Association of American Physicians.

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS

P. Thuluvath, G. Everson, S. Pol, 2011 .

Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.

G. Pantaleo, J. Bartlett, R. Steigbigel, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Experience with a cross‐study endpoint review committee for AIDS clinical trials

J. Neaton, R. Price, F. Rhame, 1998, AIDS.

Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate.

J. Justement, A. Fauci, J. Orenstein, 1988, Journal of immunology.

Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient coinfected with human immunodeficiency virus type.

P. Pierce, S. Schnittman, 1996, Clinical Infectious Diseases.

Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression

M. Hirsch, D. Richman, D. Havlir, 2001, AIDS.

Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus.

A. Fauci, H. Lane, T. Folks, 1986, Science.

Treatment of HIV-1 infection with combination therapy: Antiretroviral agents and biological response modifiers

S. Schnittman, 1994 .

Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects

K. Squires, S. Schnittman, P. Piliero, 2003, Journal of acquired immune deficiency syndromes.

Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial

D. Haas, H. Jaeger, M. Sension, 2003, AIDS.

Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals.

J. Justement, M. Baseler, A. Fauci, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals

M. Baseler, A. Fauci, H. Lane, 1989, Journal of virology.

Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding.

A. Fauci, H. Lane, S. Koenig, 1988, Journal of immunology.

Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiretroviral therapies: clues from the Fourth Conference on Retroviruses and Opportunistic Diseases.

S. Schnittman, L. Fox, 1997, AIDS research and human retroviruses.

In vivo T lymphocyte origin of macrophage-tropic strains of HIV. Role of monocytes during in vitro isolation and in vivo infection.

A. Fauci, F. Massari, A S Fauci, 1990, Journal of immunology.

Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative.

M. Holodniy, H. Standiford, S. Schnittman, 1998, The Journal of infectious diseases.

Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease.

M. Baseler, A. Fauci, H. Lane, 1990, Annals of internal medicine.

Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.

J. Bilello, G. Drusano, R. Echols, 2001, The Journal of infectious diseases.

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Ulysses Diva, Vinod K Rustgi, P. Thuluvath, 2012, The Lancet. Infectious diseases.

Epidermal Langerhans cells are not principal reservoirs of virus in HIV disease.

H. Gendelman, J. Orenstein, M. Meltzer, 1991, Journal of immunology.

Host defense against Mycobacterium-avium complex.

A. Fauci, H. Lane, L. L. Gosey, 1988, Journal of clinical immunology.

T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment

M. Lederman, D. Peterson, R. Koup, 2003, AIDS.

Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study

Marco Mancini, M. Egholm, M. Kozal, 2010, PloS one.

A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection.

R. Davey, M. Baseler, S. Vogel, 1994, The Journal of infectious diseases.

Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes.

C. Fox, A. Fauci, G. Pantaleo, 1996, The Journal of infectious diseases.

Human immunodeficiency virus and acquired immunodeficiency syndrome: an update.

A. Fauci, S. Schnittman, 1994, Advances in internal medicine.

Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis.

J. Ioannidis, S. Bozzette, M. McIntosh, 1999, Controlled clinical trials.

Phenotypic variability of lymphocyte populations in peripheral blood and lymph nodes from HIV-infected individuals and the impact of antiretroviral therapy. DATRI 003 Study Group. Division of AIDS Treatment Research Initiative.

A. Landay, S. Schnittman, J. Bethel, 1998, AIDS research and human retroviruses.

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia: genetic screening is unnecessary.

R. Bertz, R. Nettles, S. Schnittman, 2006, The Journal of infectious diseases.

Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents

L. Mofenson, G. Aldrovandi, C. Fletcher, 2011, AIDS.

Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials

Adriano Lazzarin, J. Gatell, A. Lazzarin, 2004, Journal of the International Association of Physicians in AIDS Care.

Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infections.

A. Fauci, Z. Rosenberg, S. Schnittman, 1991, Annals of the New York Academy of Sciences.

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

P. Thuluvath, G. Everson, S. Pol, 2012, The Lancet. Infectious diseases.